Kurve Technology has announced that Seurat Therapeutics will use Kurve’s intranasal delivery technology for Seurat’s IGF-1 nasal aerosol for the treatment and prevention of migraines. Details of the development and collaboration agreement were not disclosed.
In October 2018, Seurat announced that it had received a ~$510,000 grant from the National Institute of Neurological Disorders and Stroke for development of the nasal spray. Kurve has already working on several CNS projects, including a contract from the US Department of Defense for testing of a traumatic brain injury therapy.
Kurve Technology CEO Marc Giroux said, “Both Seurat and Kurve are proud to be a part of making an effort to address the efficacy of migraine management. When Seurat co-founders, Dr. Richard Kraig, Dr. Martin Sanders and Yuan Zhang contacted me regarding this therapy, it was a natural fit. As a company, Kurve has been interested in this area for some time and Seurat’s approach offers a real opportunity. It’s an exciting time with this agreement to be moving forward with our proprietary technology platform.”
Giroux continued, “We are pleased to see our business model of superior technology in a device that offers brand loyalty and market strength through the base unit and replaceable cartridges be accepted by Seurat and we foresee a bright future.”
Read the Kurve Technology press release.
